https://orcid.org/0000-0002-1137-7669
References
- Lammers T, Rizzo LY, Storm G, et al. Personalized nanomedicine. Clin Cancer Res. 2012;18(18):4889–4894.
- Ke X, Shen LS. Molecular targeted therapy of cancer: the progress and future prospect. Front Lab Med. 2017;1(2):69–75.
- Izar B, Rotow J, Gainor J, et al. Pharmacokinetics, clinical indications, and resistance mechanisms in molecular targeted therapies in cancer. Pharmacol Rev. 2013;65(4):1351–1395.
- Fass L. Imaging and cancer: a review. Mol Oncol. 2008;2(2):115–152.
- Czernin J, Weber WA, Herschman HR. Molecular imaging in the development of cancer therapeutics. Annu Rev Med. 2006;57:99–118.
- Kievit FM, Zhang M. Cancer nanotheranostics: improving imaging and therapy by targeted delivery across biological barriers. Adv Mater. 2011;23(36):H217–47.
- He J, Li C, Ding L, et al., Tumor targeting strategies of smart fluorescent nanoparticles and their applications in cancer diagnosis and treatment. Adv Mater. 2019;31(40): e1902409.
- Kang H, Stiles WR, Baek Y, et al. Renal clearable theranostic nanoplatforms for gastrointestinal stromal tumors. Adv Mater. 2020;32(6):e1905899.
- Tham HP, Xu K, Lim WQ, et al. Microneedle-assisted topical delivery of photodynamically active mesoporous formulation for combination therapy of deep-seated melanoma. ACS Nano. 2018;12(12):11936–11948.
- Kallu J, Banerjee T, Sulthana S, et al. Nanomedicine-assisted combination therapy of NSCLC: new platinum-based anticancer drug synergizes the therapeutic efficacy of ganetespib. Nanotheranostics. 2019;3(1):120–134.
- Juthani R, Madajewski B, Yoo B, et al. Ultrasmall core-shell silica nanoparticles for precision drug delivery in a high-grade malignant brain tumor model. Clin Cancer Res. 2020;26(1):147–158.
- Nebu J, Anjali Devi JS, Aparna RS, et al. Erlotinib conjugated gold nanocluster enveloped magnetic iron oxide nanoparticles–A targeted probe for imaging pancreatic cancer cells. Sens Actuators B Chem. 2018;257:1035–1043.
- Gao Y, Zhang H, Zhang Y, et al., Erlotinib-guided self-assembled trifunctional click nanotheranostics for distinguishing druggable mutations and synergistic therapy of nonsmall cell lung cancer. Mol Pharm. 2018;15(11): 5146–5161.
- Zhang Y, Zhang L, Lin X, et al. Dual-responsive nanosystem for precise molecular subtyping and resistant reversal of EGFR targeted therapy. Chem Eng J. 2019;372:483–495.
- Peng F, Setyawati MI, Tee JK, et al. Nanoparticles promote in vivo breast cancer cell intravasation and extravasation by inducing endothelial leakiness. Nat Nanotechnol. 2019;14(3):279–286.